Neuronetics (STIM) Competitors $3.52 +0.02 (+0.43%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. KMTS, SIBN, IRMD, CBLL, EMBC, BBNX, AVNS, BVS, KIDS, and RXSTShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Embecta (EMBC), Beta Bionics (BBNX), AVANOS MEDICAL (AVNS), Bioventus (BVS), OrthoPediatrics (KIDS), and RxSight (RXST). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors Kestra Medical Technologies SiBone iRadimed CeriBell Embecta Beta Bionics AVANOS MEDICAL Bioventus OrthoPediatrics RxSight Kestra Medical Technologies (NASDAQ:KMTS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment. Does the media refer more to KMTS or STIM? In the previous week, Kestra Medical Technologies had 3 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Kestra Medical Technologies and 1 mentions for Neuronetics. Kestra Medical Technologies' average media sentiment score of 0.15 beat Neuronetics' score of 0.00 indicating that Kestra Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in KMTS or STIM? 53.6% of Neuronetics shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend KMTS or STIM? Kestra Medical Technologies presently has a consensus price target of $27.50, suggesting a potential upside of 80.45%. Neuronetics has a consensus price target of $5.50, suggesting a potential upside of 56.47%. Given Kestra Medical Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Kestra Medical Technologies is more favorable than Neuronetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kestra Medical Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Neuronetics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, KMTS or STIM? Kestra Medical Technologies has higher earnings, but lower revenue than Neuronetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKestra Medical TechnologiesN/AN/AN/AN/AN/ANeuronetics$74.89M3.10-$43.71M-$1.31-2.68 Is KMTS or STIM more profitable? Kestra Medical Technologies has a net margin of 0.00% compared to Neuronetics' net margin of -53.67%. Kestra Medical Technologies' return on equity of 0.00% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Kestra Medical TechnologiesN/A N/A N/A Neuronetics -53.67%-174.15%-38.41% SummaryKestra Medical Technologies beats Neuronetics on 8 of the 11 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.11M$6.82B$5.58B$9.03BDividend YieldN/A1.29%5.25%4.03%P/E Ratio-2.6825.6027.1820.17Price / Sales3.1090.30415.50184.26Price / CashN/A20.6637.0657.97Price / Book6.174.788.085.60Net Income-$43.71M$174.76M$3.16B$248.50M7 Day Performance3.23%1.57%3.64%5.07%1 Month Performance-7.26%0.59%3.78%7.53%1 Year Performance90.00%14.24%34.08%21.54% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics1.6358 of 5 stars$3.52+0.4%$5.50+56.5%+92.3%$232.11M$74.89M-2.68180News CoverageKMTSKestra Medical TechnologiesN/A$14.75-5.9%$27.50+86.4%N/A$804.64M$52.64M0.00300News CoverageSIBNSiBone4.0437 of 5 stars$18.01-2.5%$22.50+24.9%+37.1%$787.09M$167.18M-28.14350News CoverageIRMDiRadimed4.6171 of 5 stars$59.02-4.5%$72.00+22.0%+37.0%$785.79M$73.24M38.08110CBLLCeriBell2.3967 of 5 stars$17.20-9.1%$32.14+86.9%N/A$684.19M$65.44M0.00N/AInsider TradeEMBCEmbecta4.5607 of 5 stars$10.03-2.8%$19.33+92.8%-9.7%$603.13M$1.08B11.142,100News CoveragePositive NewsBBNXBeta BionicsN/A$13.40-0.9%$23.44+75.0%N/A$586.18M$65.12M0.00294AVNSAVANOS MEDICAL1.5341 of 5 stars$11.87-3.9%N/A-36.2%$571.11M$687.80M-1.422,227News CoverageNegative NewsBVSBioventus3.3063 of 5 stars$6.82-2.8%$13.75+101.6%+16.2%$560.22M$567.70M-11.181,200News CoveragePositive NewsAnalyst ForecastKIDSOrthoPediatrics4.335 of 5 stars$21.24-5.5%$35.83+68.7%-31.6%$545.96M$204.73M-12.14200News CoveragePositive NewsRXSTRxSight2.3506 of 5 stars$12.43-4.8%$37.90+204.9%-86.1%$530.31M$139.93M-18.55220Trending NewsAnalyst Forecast Related Companies and Tools Related Companies KMTS Competitors SIBN Competitors IRMD Competitors CBLL Competitors EMBC Competitors BBNX Competitors AVNS Competitors BVS Competitors KIDS Competitors RXST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
